This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Lushi also to serve on Company’s audit committee
PATTERSON, N.J., Feb. 10, 2020 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation producats using the Company’s proprietary Deep Transcranial Magnetic Stimulation (dTMS) technology for the treatment of major depressive disorder (MDD) and Obsessive Compulsive Disorder (OCD), announced today that Mr. Avner Lushi will be joining its board of directors and will also serve as a member of its audit committee. The announcement comes after the recent shareholder approval of his election to the board.
“Avner is an accomplished business leader with close to 20 years of experience in the healthcare industry as well as in general management, strategy and finance. I am confident that his diverse skillset will add depth to our board and will significantly contribute to the support and guidance we provide our management team,” said Dr. David Zacut, chairman of the board.
“I am impressed by the progress BrainsWay has made in recent years,” said Mr. Lushi. “Its consistent commercial excellence, multiple successful multicenter clinical studies – including the very recent smoking cessation study, proprietary technology, rich R&D pipeline, recent listing on the NASDAQ and appointment of a highly accomplished U.S.-based CEO are all achievements which serve to position the company for growth. I am honored to join the company’s board, and look forward to working with my fellow board members and the executive management team in order to achieve the company’s long-term strategic objectives and enhance shareholder value.”
About Avner Lushi
Mr. Lushi has broad experience in the healthcare industry, and has served in a wide range of roles including as an entrepreneur and venture capital investor.
In 2015, he co-founded the Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF), a $100 million fund focused on introducing Israeli and western life sciences companies to the Chinese market, where he also serves as a Managing Partner & CEO. From 2004 to 2015, Mr. Lushi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV), a prominent Israeli life sciences venture capital fund. Before joining IHCV, he was the Co-Founder & CEO of Life Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking.
In addition to his expertise in the life sciences arena, Mr. Lushi also served as an independent board member at multiple publicly traded companies, including most recently at Raval ICS Ltd. and Ram-On Investments and Holdings (1999) Ltd. Prior to turning to the private sector, he held senior advisory positions at the Israeli Prime Minister’s office and the Israeli Supreme Court.
Mr. Lushi holds an LLM degree from the Hebrew University of Jerusalem, as well as an LLB in Law and BA in Economics from Haifa University.
BrainsWay is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the Company is based on a unique breakthrough technology called dTMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company’s device has been FDA cleared for the treatment of major depressive disorder (MDD) and of Obsessive Compulsive Disorder (OCD). The Company’s systems have also received CE clearance and are used worldwide for the treatment of various brain disorders.